{
  "id": 2917724,
  "title": "Moderna-Merck cancer vaccine success marks breakthrough for personalised mRNA treatment",
  "url": "https://urgent.news/2026/08/24/moderna-merck-cancer-vaccine-success-marks-breakthrough-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T02:02:00.000Z",
  "source": {
    "name": "The Vibes",
    "slug": "the-vibes",
    "url": "https://www.thevibes.com/articles/news/126515/moderna-merck-cancer-vaccine-success-marks-breakthrough-for-personalised-mrna-treatment"
  },
  "original_language": "en",
  "account": "A personalized mRNA-based cancer vaccine developed by Moderna and Merck & Co. has shown promising results in a large-scale melanoma trial, potentially marking a breakthrough in personalized cancer treatment. This marks the first time an mRNA-based cancer vaccine has achieved success in a large-scale study, generating significant optimism within the scientific community. The vaccine reduces the rate of melanoma recurrence in patients who have undergone surgery, a population particularly susceptible to disease recurrence. Unlike traditional vaccines designed to prevent infectious diseases, this personalized vaccine trains the immune system to recognize and attack specific mutations found in a patient's tumor cells. The treatment approach involves analyzing a patient's tumor sample, identifying mutations most likely to trigger an immune response, and incorporating up to 34 personalized mutations into the vaccine. Despite the promising outcomes, key details such as the magnitude of the benefit and potential for longer survival remain undisclosed. The companies are continuing to gather longer-term data, with full results expected to be presented at an upcoming scientific meeting. This successful trial has spurred further interest in developing mRNA-based cancer vaccines, with Moderna and Merck testing the approach in other cancers like lung, bladder, and kidney tumors. Similar research is underway by other companies like BioNTech and Roche, who are also exploring personalized mRNA cancer vaccines for diseases including pancreatic and colon cancer. While the vaccine does not establish mRNA technology as a cure for cancer, the results offer compelling evidence that the approach can effectively teach the immune system to target individual tumor mutations, potentially transforming personalized cancer treatment.",
  "summary": "A PERSONALISED mRNA-based cancer vaccine developed by Moderna and Merck & Co. has delivered a landmark result in a late-stage melanoma trial, strengthening hopes that technology originally propelled into the mainstream by Covid-19 vaccines could even...",
  "key_points": [
    "Moderna and Merck's personalized mRNA cancer vaccine shows success in melanoma trial.",
    "Vaccine reduces melanoma recurrence in post-surgery patients.",
    "Treatment identifies and incorporates up to 34 tumor-specific mutations."
  ],
  "editors_take": "This successful trial marks a breakthrough in personalized cancer treatment, establishing mRNA-based vaccines as a viable approach to teaching the immune system to target individual tumor mutations.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Vibes",
        "title": "Moderna-Merck cancer vaccine success marks breakthrough for personalised mRNA treatment",
        "url": "https://urgent.news/2026/08/24/moderna-merck-cancer-vaccine-success-marks-breakthrough-for-2917725",
        "published": "2026-08-24T02:02:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}